A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment

75Citations
Citations of this article
169Readers
Mendeley users who have this article in their library.

Abstract

Breast cancer is the most common malignancy worldwide, especially among women, with substantial after-treatment effects. The survival rates of breast cancer have decreased over the years even with the existence of various therapeutic strategies, specifically, chemotherapy. Clinical drugs administered for breast cancer appear to be non-targeting to specific cancer sites leading to severe side effects and potentially harming healthy cells instead of just killing cancer cells. This leads to the need for designing a targeted drug delivery system. Nanomaterials, both organic and inorganic, are potential drug nanocarriers with the ability of targeting, imaging and tracking. Various types of nanomaterials have been actively researched together with their drug conjugate. In this review, we focus on selected nanomaterials, namely solid-lipid, liposomal, polymeric, magnetic nanoparticles, quantum dots, and carbon nanotubes and their drug conjugates, for breast cancer studies. Their advantages, disadvantages and previously conducted studies were highlighted.

Cite

CITATION STYLE

APA

Lee, J. J., Yazan, L. S., & Abdullah, C. A. C. (2017, March 27). A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment. International Journal of Nanomedicine. Dove Medical Press Ltd. https://doi.org/10.2147/IJN.S127329

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free